Independent Pharmacies Say Drug Middlemen Are Making Them Sick
Published by Bloomberg Health Care Blog
Independent pharmacy groups in several states are sick of the low insurance reimbursement rates that middlemen, known as pharmacy benefit managers, or PBMs, pay them after drugs are dispensed and they’re pushing for greater oversight of the drug middlemen.
PBMs include companies like Express Scripts Holding Co., CVS Health Corp.’s Caremark, and UnitedHealth Group Inc.’s OptumRx, and independent pharmacies say those companies’ practices may threaten the survival of nonchain pharmacies.
The PBM reimbursement rates and post-sale fees they charge pharmacies are challenging the survival of independent pharmacies, according to the Alexandria, Va.-based National Community Pharmacists Association, a trade association for independent pharmacies, more than 80 percent of which are located in small population centers.
Moves are afoot in state legislatures, including Arkansas and Kentucky, to increase government regulation of PBMs.
In Kentucky, for example, a state Senate committee approved a bill Feb. 14 that would end state Medicaid payments to pharmacy benefit managers for managing the state program and let the state use the money to administer its own pharmacy benefits program.
“[PBMs] currently set all the rules with little to no government oversight,” Kentucky state Sen. Max Wise (R) said in a statement. “As a state senator, taxpayer, I don’t think that’s right.”
Recent Posts
-
SCPC Applauds Bipartisan Group of Lawmakers Calling for Critical Changes to Medicare Drug Price Negotiations
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement commending Chairman Buddy Carter, Rep. Jake Auchincloss and other Members of Congress for urging HHS and CMS to examine the looming impact of Medicare drug price negotiations on America’s pharmacies.
-
SCPC Releases Statement in Support of Government Accountability Office (GAO) Report on the Inflation Reduction Act
SCPC has repeatedly warned about the impact of the Inflation Reduction Act’s (IRA) mandatory Medicare drug price negotiations on LTC pharmacies and the millions of vulnerable seniors they serve. We are glad the Government Accountability Office (GAO) is examining how these policies are affecting pharmacies, particularly LTC pharmacies, which already operate under a broken reimbursement model that often requires them to dispense many of the most commonly used medications at a loss.
-
SCPC Applauds President Trump’s Executive Order Calling on HHS and Congress to Improve the IRA, Rein In PBMs and Lower Drug Costs
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement applauding President Trump’s recent Executive Order aimed at improving the Inflation Reduction Act (IRA), lowering drug prices and addressing the harmful actions of PBMs. “For far too long, pharmacy benefit managers (PBMs) have taken […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.